Linked Life Data

3286509

Source:http://linkedlifedata.com/resource/pubmed/id/3286509

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1988-7-8
pubmed:abstractText
In a randomized multicenter study, ciprofloxacin and norfloxacin, each in two different dose regimens and in combination with non-absorbable antimycotics, were administered to 51 patients with acute leukaemia undergoing aggressive remission induction chemotherapy for infection prevention. Both drugs showed an effective elimination of gram-negative potential pathogens and Staphylococcus aureus not affecting the anaerobic flora of the gastrointestinal tract. A low incidence of side effects and a satisfactory patient compliance could be observed. A daily dosage of 1,000 mg ciprofloxacin or 800 mg norfloxacin is recommended for infection prevention in severely granulocytopenic patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0300-8126
pubmed:author
pubmed:issnType
Print
pubmed:volume
16
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
98-104
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:articleTitle
Ciprofloxacin and norfloxacin for selective decontamination in patients with severe granulocytopenia.
pubmed:affiliation
Department of Internal Medicine, Haematology and Oncology, Evangelisches Krankenhaus, Essen-Werden.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial